Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1160502 | 0.99 | KDM4E (0.57) | KDM4EHTTALDH1A1HPGDTSHR | |
| SCHEMBL11891125 | 0.87 | KDM4E (0.55) | KDM4ETSHRSMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL1160543 | 0.85 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2MAPTBCHETP53 | |
| SCHEMBL11890508 | 0.85 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2MAPTBCHETP53 | |
| Hydrochloric Acid SCHEMBL13276206 | 0.84 | SMN1; SMN2 (0.71) | ALDH1A1SMN1; SMN2MAPTBCHETP53 | |
| SCHEMBL11890502 | 0.84 | KDM4E (0.73) | KDM4ETSHRSMN1; SMN2MAPTBCHE | |
| SCHEMBL23118938 | 0.83 | KDM4E (0.53) | KDM4EHTTALDH1A1HPGDTSHR | |
| SCHEMBL17826523 | 0.83 | ALDH1A1 (0.55) | KDM4EHTTALDH1A1HPGDTSHR | |
| SCHEMBL2584579 | 0.83 | KDM4E (0.58) | KDM4EHTTALDH1A1HPGDTSHR | |
| Avanbulin SCHEMBL29374555 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1HPGDTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459553-B1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| EP-2459553-B1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-8802858-B2 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802858-B2 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802858-B2 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
| EP-2459553-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | Basilea Pharmaceutica AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012577-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | SSB, VHL, AHR | KDM4E 926/4885HTT 1879/4885ALDH1A1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.